EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms

Cecilia Pesini, Mario Gil-Bellido, Lorena S Millan, Carmen Oñate, Adanays Calvo-Pérez, Llipsy Santiago, Eldris Iglesias, Jorge Paúl Bernal, Miguel Araujo-Voces, Laura Paz Artigas, Laura García-Martínez, Francisco J Roig und 12 weitere

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2025-012706 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Cecilia Pesini und 23 weiteren Autor:innen. Beteiligte Einrichtung: Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain. Hauptthemen laut MEDLINE: Calreticulin, Receptors, Chimeric Antigen, T-Lymphocytes, Myeloproliferative Disorders. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The adoptive transfer of T cells engineered to express chimeric antigen receptors (CAR-T) has shown high efficacy and safety in treating various hematologic malignancies. However, many hematologic disorders, such as BCR::ABL1-negative myeloproliferative neoplasms (MPNs), lack effective treatment options. Some of these neoplasms are marked by a recurrent mutation that results in the expression of mutant calreticulin (mCALR), a neoantigen absent in healthy tissues, making it a highly specific and appealing target for CAR-T cell therapy.

Methods

Five distinct CARs were designed based on available monoclonal antibody sequences that target mCALR and were subsequently used to generate CAR-T cells. The most effective construct was selected through functional in vitro assays against mCALR-positive cell lines. Its efficacy was then evaluated in cell lines, patient-derived cells, and orthotopic xenograft models, assessing tumor burden, CAR-T cell infiltration, and animal survival. Bulk and single-cell RNA sequencing were performed on patient-derived cells and residual tumor cells from CART-treated mice, respectively, to investigate potential resistance mechanisms. The impact of the most relevant pathway alteration on CAR-T efficacy was also analyzed. Pharmacological rescue assays using targeted agents were then conducted.

Results

Among the five constructs, one demonstrated superior and specific cytotoxicity against mCALR-expressing cells, with no activity against mCALR-negative controls. This CAR-T cell also eliminated patient-derived MPN cells and controlled disease progression in xenograft models, which correlated with the persistence of CAR-T cells and tumor infiltration. Transcriptomic profiling of patient samples and residual tumor cells in spleens of treated mice revealed upregulation of anti-apoptotic proteins. Functional assays confirmed reduced CAR-T efficacy in Bcl-2 high cells, which was restored by co-treatment with venetoclax, indicating a viable combination approach to overcome resistance.

Conclusions

This study demonstrates, for the first time, the successful targeting of mCALR with CAR-T cells as a therapeutic strategy for MPNs. The chosen construct shows strong preclinical efficacy against established cell lines and patient-derived cells. Additionally, transcriptomic profiling uncovered apoptosis resistance mechanisms and supports a combination strategy with BH3 mimetics, such as venetoclax. These findings provide a compelling rationale for ongoing preclinical development and future clinical application of anti-mCALR CAR-T cells for the treatment of MPNs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CalreticulinReceptors, Chimeric AntigenT-LymphocytesMyeloproliferative DisordersMutationHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysImmunotherapy, AdoptiveBone Marrow NeoplasmsGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Adoptive cell therapy - ACTChimeric antigen receptor - CARCoagulopathyHematologic MalignanciesImmunotherapy

Substanzen

CalreticulinReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Aragón Health Research Institute (IIS Aragón), Zaragoza, Spain.
  • CIBERINFEC, Carlos III Health Institute, Madrid, Spain, Spain.
  • Red RICOS de Terapias Avanzadas TERAV+, Carlos III Health Institute, Madrid, Spain.
  • CERTERA, Consorcio Estatal en Red para el desarrollo de Medicamentos de Terapias Avanzadas, Carlos III, Madrid, Spain.
  • Department of Microbiology, Pediatry, Radiology and Public Health, University of Zaragoza, Zaragoza, Spain.
  • Unidad de Nanotoxicología e Inmunotoxicología experimental, IIS Aragón, Zaragoza, Spain.

Zitieren

APA

Pesini, C., Gil-Bellido, M., S Millan, L., Oñate, C., Calvo-Pérez, A., Santiago, L., Iglesias, E., Bernal, J. P., Araujo-Voces, M., Paz Artigas, L., García-Martínez, L., Roig, F. J., Movilla Meno, N., Garcia-Aznar, J. M., Menéndez-Jandula, B., Olave, M. T., Azaceta Reinares, G., Garrote, M., Alvarez-Larrán, A., …, & Ramirez-Labrada, A. (2026). Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-012706

Vancouver

Pesini C, Gil-Bellido M, S Millan L, Oñate C, Calvo-Pérez A, Santiago L, et al. Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-012706

BibTeX
@article{Pesini2026,
  author = {Pesini, Cecilia and Gil-Bellido, Mario and S Millan, Lorena and Oñate, Carmen and Calvo-Pérez, Adanays and Santiago, Llipsy and Iglesias, Eldris and Bernal, Jorge Paúl and Araujo-Voces, Miguel and Paz Artigas, Laura and García-Martínez, Laura and Roig, Francisco J and Movilla Meno, Nieves and Garcia-Aznar, José Manuel and Menéndez-Jandula, Bárbara and Olave, María Teresa and Azaceta Reinares, Gemma and Garrote, Marta and Alvarez-Larrán, Alberto and Gálvez, Eva M and Sánchez Martínez, Diego and Arias, Maykel A and Pardo, Julian and Ramirez-Labrada, Ariel},
  title = {Mutant calreticulin enables potent and selective CAR-T cell therapy in preclinical models of myeloproliferative neoplasms},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2025-012706}
}
Kostenlos starten →